

Sunday, January 13, 2013

Curriculum Vitae

Israel Gotsman M.D.

Date of birth: 1966. Cape Town, South Africa.

Date of Aliya: 1973

ID number: 013857867

Heart Institute,

Hadassah University Hospital,

Jerusalem, Israel

Phone: 02-6776564; Cellular: 050-4048105

Fax: 02-6411028

E-mail: Igotsman@bezeqint.net

Military Service:

Israeli Defense Forces - Armored Corps, 1984-1988

Reserve Duty, Armored Corps, 1988-present, Battalion Medical Officer, Rank: Major.

Education:

Medical School, 1988 – 1994. Hebrew University Medical School, Jerusalem, Israel.

BSc. Medical Sciences, 1991

Medical Degree. (M.D.), 1995

Post-graduate training:

Internship, General, 1995 – 1996. Sheba Medical Center, Tel Hashomer.

Residency in Internal Medicine, 1996 – 2000. Medical Division, Hadassah University Hospital, Ein-Karem, Jerusalem, Israel.

Fellowship in Cardiology, 2000 – 2004. Heart Institute, Hadassah University Hospital, Ein-Karem, Jerusalem.

Research Fellowship in Cardiovascular diseases, 2004 – 2007. The Center for Excellence in Vascular Biology, The Immunology Research Division, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School

Clinical positions & experience:

General Rotating Internship, 1995 – 1996. Sheba Medical Center, Tel Hashomer.

Residency in Internal Medicine, 1996 – 2000. Hadassah University Hospital, Ein-Karem, Jerusalem.

Senior Resident - Internal Medicine A, 1999.

Chief Resident - Department of Internal Medicine, 1999-2000.

Fellowship in Cardiology, 2000-2004. Hadassah University Hospital, Ein-Kerem, Jerusalem.

Senior Cardiologist, Heart Failure Center, Heart Institute, Hadassah University Hospital, Ein-Kerem, Jerusalem, 2007-present,

Acting Director, Heart Failure Center and Day-care Clinic, Misgav-Ladach Hospital, Jerusalem, 2009-present.

Academic appointments:

Clinical Instructor, 1998. Hebrew University, Jerusalem, Israel.

Board certification & qualifications:

ECFMG Part I, 1995 and Part II, 2000

Israeli Medical License No. 28713, 1996.

Israeli board certified in Internal Medicine, 2000. Israeli license No. 18091.

Israeli board certified in Cardiology, 2004. Israeli license No. 21715

Professional society memberships:

Israel Medical Association

Israel Heart Society.

Israel Heart Society – Working group on Heart Failure

Israel Heart Society – Working group on Cardiomyopathy

European Society of Cardiology (ESC)

Heart Failure Association of the ESC

Professional, clinical and academic activities

Senior Cardiologist and Heart Failure specialist, Heart failure and cardiomyopathy Unit, Hadassah Medical Center, 2007-present.

Heart failure consultant, Cardiology and Internal Medicine departments and clinics in cardiology, heart failure and cardiomyopathies.

Coordinator of heart failure meetings and academic activities related to the heart failure unit.

Coordinator of the weekly academic meeting of the Heart Failure unit, Hadassah 2010-2012

Coordinator of heart failure and cardiac resynchronization therapy (CRT) bi-monthly meetings, Heart Institute, Hadassah, 2008-2011.

Development of heart failure databases in Hadassah and the Kuput Holim

Clinical research in heart failure at the heart failure unit.

Active heart failure clinic with nurse supervised management, Heart failure center, Hadassah Medical Center, 2007-present

Heart failure center, Clalit health services 2008-2011.

Founder and Acting Director, Heart Failure Center and Day-care Clinic, Misgav-Ladach Hospital, Jerusalem, 2009-present.

Cardiology clinics in the health maintenance organizations (HMO's): Clalit health services (2007-2011), Maccabi Health Care (2008-2011) and Meuhedet (2009-2011)

Additional Professional and academic activities

Organizer of the Hadassah clinical conference on periodontal and cardiovascular diseases, 2007

Lecture for the public – 'Heart failure: An overview and advanced treatments'. Workshop sessions on Cardiology: 'חויית דעת' - College of Engineering Jerusalem and Hadassah Medical Center, 2009.

Organizer of Heart Failure Congress for the public. Hadassah Medical Center, February 2012.

Organizer of open house workshop for heart failure patients as part of the European Heart Failure Awareness Day, Hadassah Medical Center, May 2012.

Member of the organizing committee of the annual National Heart Failure congress of the working group on heart failure, Israel Heart Society, May 2012

Grant Reviews

Austrian Science Fund (FWF): Project number: P 23780-B11: 'CX3CR1-expressing T cells at the interface between visceral obesity and atherogenesis', 8/2011.

Reviewer of Journal manuscripts:

American Journal of Cardiology

Lancet

Atherosclerosis

Cardiology

Clinical Cardiology.

European Journal of Clinical Nutrition

Awards and Honors:

1. Prize for outstanding research abstract: the Hebrew University, Faculty of Medicine - 50th year anniversary – Jerusalem 1999.
2. Award for young investigator of the European Association for the Study of The Liver, Naples, Italy 1999.
3. Abstract prize, American Digestive Health Foundation and American Gastroenterological Association, 2000
4. American Gastroenterological Association: Poster of Distinction Award, Digestive-Disease-Week, San Diego, USA 2000.
5. Award for young investigator of the European Association for the Study of the Liver, Rotterdam, Holland 2000.
6. Research Award of the American Association for the Study of the Liver, Dallas, USA 2000.
7. **Faculty of Medicine Prize for Outstanding Research, Hebrew University, 2000:**
‘Treatment of chronic graft versus host disease by induction of oral tolerance towards recipient antigens‘
8. **The Louis Chor Memorial Trust Award for research in Cardiac Disease, 2001-2003.**
‘The role of periodontal infections as a risk and prognostic factor in Ischemic Heart Disease‘
9. **The American Physicians Fellowship for Medicine, 2003 - 2004.**
‘Immune mechanisms and responses in Atherosclerosis‘
10. **Fulbright Post-doctoral Research Award: 2004-2006.**
‘Immune-modulation in Atherosclerosis‘
11. **Merit award - Atherosclerosis Thrombosis Vascular Biology Council, AHA 2006.**
‘Deficiency of the regulatory molecules PD-L1 and PD-L2 results in increased atherosclerosis in LDLR-null mice‘

Research Grants:

1. **The Joint Research Fund of the Hebrew University and Hadassah University Hospital**, 1999. *'Induction of antigen specific oral tolerance to Hepatitis B antigen.'*
\$10,000. (Publication #2)
2. **The Israel Cancer Research Fund (ICRF) – Fellowship Grant**, 1999-2000.
'Treatment of GVHD by induction of oral tolerance towards recipient antigens'
\$36,000. (Publication #4)
3. **The Ministry of Health - 'ezvonot' Fund**, 2000. *'Induction of oral tolerance towards Hepatitis B virus.'*
IS20,000. (Publication #2).
4. **The Joint Research Fund of the Hebrew University and Hadassah University Hospital**, 2000. *'The role of immune tolerance induction towards tumor-associated antigens in growth of the Human Hepatoma cell line in mice.'*
\$10,000. (Publication #9).
5. **The Phillip Morris External research grant**, 2002-2004. *'Periodontal infections: a risk and prognostic factor in ischemic heart disease'*
\$270,000. (Publications #14 and 20).
6. **The European Union collaborative research grant:**
FP7-HEALTH-2012-INNOVATION-1, 2012-2016:
'King of hearts, joints and lungs; periodontal pathogens as etiologic factor in RA, CVD and COPD and their impact on treatment strategies'.
Euro 642,800.

Research Experience:

Basic-Science Research:

Nephrology Laboratory – Department of Medicine, Hadassah University Hospital, 1994-1996.

MD thesis. Supervisor: Prof. D. Rubinger

Thesis: *The effects of chronic administration of sub-lethal doses of human recombinant TNF- α on renal function in rats.*

Immune tolerance and modulation in liver and gastrointestinal experimental inflammatory diseases. Liver Unit Laboratory, Department of Medicine, Hadassah University Hospital, 1998-2001, Publications #1-2, 4-6, 10.

Immune-modulation in atherosclerosis. Atherosclerosis Laboratory - Center for Research, Prevention and Treatment of Atherosclerosis, Department of Medicine, Hadassah University Hospital, 2001-2003:

Immune and inflammatory mechanisms in Atherosclerosis: Cellular and molecular mechanisms of the atherosclerotic process. The Center for Excellence in Vascular Biology and the Immunology Research Division, Department of Pathology, Brigham and Women's Hospital, 2004-2007, Publications #13, 16-17, 19, 21, 32.

Clinical Research:

The characteristics of pleural effusions in patients with congestive heart failure.

Department of Medicine, Hadassah University Hospital. 1998-2000. Publication #8.

Predictors of morbidity and mortality in patients with infective endocarditis: The role of transesophageal-echocardiography. Heart Institute, Hadassah University Hospital, 2000-2003. Publication #15.

Periodontal disease and inflammatory markers in the development of coronary artery disease. Short and long-term follow-up study. Heart Institute and Department of Periodontology, 2001 - present. Publications #14 and 20.

Pharmacological compliance in heart failure. Heart Institute and Department of Clinical Pharmacology, 2001-2004, 2006-2007. Publication #18.

Heart Institute, Hadassah University Hospital, 2007-present:

Heart failure and Preserved Ejection Fraction (HFPEF): Prospective long-term clinical study on the pathophysiology, epidemiology and clinical outcome in patients hospitalized with heart failure and preserved ejection fraction. Publications #22 and 29.

Clinical and Epidemiological Research in heart failure. Ongoing clinical studies based on several large cohorts of heart failure patients (hospitalized and outpatient) with particular interest in predictors of outcome. Publications #24-25, 27, 30.

Meta-analysis Global Group in Chronic Heart Failure (MAGGIC): Collaboration with a large international group of investigators on outcomes in heart failure. Publication #28.

Heart failure management programs and clinical outcome – Clinical study of patients in a heart failure center demonstrating the impact of nurse-led specialized heart failure centers in improving outcome and functional capacity in heart failure - collaboration with Clalit Health Services. Publication #26.

Teaching Positions:

Instructor - Introductory course in Clinical Medicine and Physical Examination, 1997 - 2000.

Instructor and Tutor- 4th and 6th year Medical students, Internal Medicine, 1996 – 2000.

Instructor - Pharmaceutical students (M.Pharm.); School of Nursing and intensive care course, 2000 - 2003.

Best instructor in Internal Medicine, 1998, 1999.

Outstanding Instructor – Faculty of Medicine, Hebrew University, 2000.

Course coordinator - Internal Medicine course for Medical students, 2000.

Lecturer / Instructor -

- Cardiology Clinical rotation - 6th year medical students, 2000-2004, 2007-present.
- Introductory course in Cardiology for 4th year medical students, 2009 – present.
- Internal Medicine clinical rotation (Cardiology) 4th year medical students, 2000-2004, 2007-present.
- Advanced Cardiac Life Support (ACLS) course, 2001-2004, 2007-present
- Coordinator and lecturer: Heart Failure Course for Physicians, Clalit health services, 2010
- Cardiology Course for Clinical Nurses, Clalit health services, 2008-present

Course Coordinator - Cardiology Clinical rotation - 6th year medical students, 2009 – 2010.

Students:

- Clinical Supervisor of Medical Student Dror Nitzan - MD thesis, 2003-2004:
'Induction of Oral Tolerance towards Atherosclerotic Plaque Antigens (Oxidized-LDL) Attenuates Atherosclerosis in Apo-E-Deficient Mice'
- Clinical Supervisor of Master student in pharmacology Shani Rubonivich, 2001-2003:
'The Utilization of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Congestive Heart Failure: An Observational Study of Treatment Rates and Clinical Outcome', Publication #18.
- Clinical Supervisor of Master student in nursing Hadar Bornstein, 2011-2012:
'הקשר בין רמת סיפוק מחיי נישואין ובין רמות חרדה ודיכאון בקרב מטופלים לפני וחוודש אחרי צנתור לבבי אלקטיבי ראשון'

- Clinical Supervisor of Medical Student Aviad Katz - MD thesis, 2012:
'Does the Electrocardiographic frontal QRS-T Angle predict increased risk in Hypertrophic Cardiomyopathy'

List of Publications:

Original papers in peer-reviewed journals:

1. Trop S, Samsonov D, **Gotsman I**, Alper R, Diament J, Ilan Y. Liver associated lymphocytes expressing NK1.1 are essential for oral immune tolerance induction. *Hepatology* 1999; 29(3): 746-55. **(Impact Factor 7.3)**
2. **Gotsman I**, Beinart R, Alper R, Zeira M, Rabani E, Engelhardt D, Gorecki M, Ilan Y. Induction of oral tolerance towards hepatitis B envelope antigens in a murine model. *Antiviral Res.* 2000; 48(1): 17-26. **(Impact factor: 4.3)**
3. Weinberg I, Vasiliev L, **Gotsman I**. Anti-dsDNA Antibodies in Sarcoidosis. *Semin Arthritis Rheum.* 2000; 29(5): 328-31. **(Impact factor: 3.3)**
4. Ilan Y, **Gotsman I**, Pines M, Beinart R, Alper R, Zeira M, Rabani E, Engelhardt D, Roy Chowdhury N, Roy Chowdhury J, Nagler A. Treatment of chronic graft versus host disease by induction of oral tolerance towards recipient antigens. *Blood* 2000; 95(11): 3613-9. **(Impact factor: 8.78)**
5. Shlomai A, Trop S, **Gotsman I**, Yurim O, Diament J, Alper R, Rabani E, Engelhardt D, Ilan Y. Immune-modulation of the Th1/Th2 paradigm in experimental colitis: the role of surrogate antigens-bystander effect and NK1.1 liver lymphocytes. *J Pathology* 2001; 195(4):498-507. **(Impact factor: 4.1)**
6. **Gotsman I**, Shlomai A, Alper R, Rabani E, Engelhardt D, Ilan Y. Amelioration of immune-mediated experimental colitis: tolerance induction in the presence of preexisting immunity and surrogate antigen bystander effect. *J Pharmacol Exp Ther.* 2001; 297(3):926-32. **(Impact factor: 3.7)**
7. **Gotsman I**, Mushkat M. Glucose-6-dehydrogenase deficiency increases the initial severity of viral hepatitis A. *J Gastroenterol Hepatol.* 2001; 16(11):1239-43. **(Impact factor: 1.3)**
8. **Gotsman I**, Fridlender Z, Meirovitz A, Dratva D, Muszkat M. The Evaluation of Pleural Effusion in Congestive Heart Failure. *Am J Med.* 2001; 111(5):375-8. **(Impact Factor: 6.1)**
9. **Gotsman I**, Israeli D, Alper R, Rabani E, Engelhardt D, Ilan Y. Induction of immune tolerance towards tumor-associated-antigens enables growth of Human Hepatoma in mice. *Int J Cancer.* 2002; 97(1):52-7. **(Impact factor: 4.0)**

10. **Gotsman I**, Israeli D, Alper R, Klein A, Rabani E, Engelhardt D, Ilan Y. Induction of oral immune-regulation towards hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice. *Cancer*. 2002 Jan 15;94(2):406-14. (**Impact factor: 3.9**)
11. **Gotsman I**, Lotan C, Mosseri M. Clinical manifestations and outcome of acute myocardial infarction in very young patients. *Isr Med Assoc J*. 2003 Sep;5(9):633-6. (**Impact Factor: 0.6**)
12. Menachem Y, **Gotsman I**. Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. *Isr Med Assoc J*. 2004 Feb;6(2):88-90. (**Impact Factor: 0.5**)
13. **Gotsman I**, Grabie N, Gupta R, Dacosta R, Sukhov G, Witztum JL, Sharpe AH, Lichtman AH. Impaired Regulatory T-Cell Response and Enhanced Atherosclerosis in the Absence of Inducible Costimulatory Molecule. *Circulation* 2006 Nov 7;114(19):2047-55. (**Impact Factor: 12.7**)
14. **Gotsman I**, Lotan C, Soskolne WA, Rassovsky S, Pugatsch T, Lapidus L, Novikov Y, Masrawa S, Stabholz A. Periodontal destruction is associated with coronary artery disease and periodontal infection with acute coronary syndrome. *J Periodontol*. 2007;78:849-58. (**Impact Factor: 2.2**)
15. **Gotsman I**, Meirovitz A, Meizlish N, Gotsman M, Lotan C, Gilon D. Clinical and echocardiographic predictors of morbidity and mortality in infective endocarditis: the significance of vegetation size. *Isr Med Assoc J*. 2007;9:365-9. (**Impact Factor: 0.6**)
16. Grabie N, **Gotsman I**, DaCosta R, Pang H, Stavrakis G, Butte MJ, Keir ME, Freeman GJ, Sharpe AH, Lichtman AH. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. *Circulation*. 2007;116:2062-71. (**Impact Factor: 12.7**)
17. **Gotsman I**, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. *J Clin Invest*. 2007;117:2974-82. (**Impact Factor: 16.9**)
18. **Gotsman I**, Shani R, Azaz-Livshits T. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome. *Isr Med Assoc J*. 2008;10:214-8. (**Impact Factor: 0.9**)

19. Rocha VZ, Folco EJ, Sukhova G, Shimizu K, **Gotsman I**, Vernon AH, Libby P. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. *Circ Res*. 2008;103:467-76. **(Impact Factor: 9.98)**
20. **Gotsman I**, Stabholz A, Planer D, Pugatsch T, Lapidus L, Novikov Y, Masrawa S, Soskolne A, Lotan C. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? *Isr Med Assoc J*. 2008;10:494-8. **(Impact Factor: 0.9)**
21. Packard RR, Maganto-Garcia E, **Gotsman I**, Tabas I, Libby P, Lichtman AH. CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. *Circ Res*. 2008;103:965-73. **(Impact Factor: 9.98)**
22. **Gotsman I**, Zwas D, Planer D, Azaz-Livshits T, Admon D, Lotan C, Keren A. Clinical outcome of patients with heart failure and preserved left ventricular function. *Am J Med*. 2008;121:997-1001. **(Impact Factor: 5.5)**
23. Nassar H, **Gotsman I**, Gerganski P, Moseri M, Lotan C, Gotsman M. Cutting balloon angioplasty and stent implantation for aorto-ostial lesions: clinical outcome and 1-year follow-up. *Clin Cardiol*. 2009;32:183-186. **(Impact Factor: 1.1)**
24. **Gotsman I**, Zwas D, Planer D, Admon D, Lotan C, Keren A. The significance of serum urea and renal function in patients with heart failure. *Medicine (Baltimore)*. 2010;89:197-203. **(Impact Factor: 5.1)**
25. **Gotsman I**, Zwas D, Admon D, Lotan C, Keren A. Seasonal variation in hospital admission in patients with heart failure and its effect on prognosis. *Cardiology* 2010;117(4):268-74. **(Impact Factor: 1.6)**
26. **Gotsman I**, Zwas D, Zemora Z, Jabara R, Admon D, Lotan C, Keren A. Clinical outcome of patients with chronic heart failure followed in a specialized heart failure center. *Isr Med Assoc J* 2011;13:468-73. **(Impact Factor: 0.9)**
27. **Gotsman I**, Shauer A, Zwas DR, Hellman Y, Keren A, Lotan C, Admon D. Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. *Eur J Heart Fail* 2012;14:357-66. **(Impact Factor: 4.9)**

28. McAlister FA, Ezekowitz J, Tarantini L, Squire I, Komajda M, Bayes-Genis A, **Gotsman I**, Whalley G, Earle N, Poppe KK, Doughty RN. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new chronic kidney disease-epidemiology collaboration group formula. *Circ Heart Fail* 2012;5:309-14.
29. **Gotsman I**, Zwas D, Lotan C, Keren A. Heart failure and preserved left ventricular function: long term clinical outcome. *PLoS One* 2012;7:e41022.
30. **Gotsman I**, Keren A, Lotan C, Zwas DR. Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. *J Card Fail* 2012;18:694-701.
31. **Gotsman I**, Keren A, Hellman Y, Banker J, Lotan C, Zwas DR. Usefulness of the Electrocardiographic Frontal QRS-T Angle to Predict Increased Morbidity and Mortality in Patients with Chronic Heart Failure. In-press *Am J Cardiol* 2013.

Reviews

32. **Gotsman I**, Sharpe AH, Lichtman AH. T-cell costimulation and coinhibition in atherosclerosis. *Circ Res.* 2008;103:1220-1231. **(Impact Factor 9.98)**
33. Zwas DR, **Gotsman I**, Admon D, Keren A. Advances in the differentiation of constrictive pericarditis and restrictive cardiomyopathy. *Herz* 2012;37:664-673.
34. Shauer A, **Gotsman I**, Keren A, Zwas DR, Hellman Y, Durst R, Admon D. Acute Viral Myocarditis: Current Concepts in Diagnosis and Treatment. In-press, *Isr Med Assoc J.* 2012.

Editorials

35. **Gotsman I**, Gupta R, Lichtman AH. The influence of the regulatory T lymphocytes on atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2007;27:2493-5. **(Impact Factor 7.2)**
36. **Gotsman I**, Lichtman AH. Targeting interferon-gamma to treat atherosclerosis. *Circ Res.* 2007;101:333-4. **(Impact Factor 9.85)**

Case Reports - peer-reviewed:

37. **Gotsman I**, Mogle P, Shapira MY. An unusual cause of dysphagia. *Postgrad Med J.* 1999; 75(888):629-31.

38. **Gotsman I**, Azaz-Livshits T, Fridlender Z, Muszkat M, Ben-Chetrit E. Mefloquine induced acute Hepatitis. *Pharmacotherapy* 2000; 20(12):1517-9
39. **Gotsman I**, Elhallel-Darnitski M, Friedlander Z, Haviv YS. Beta-interferon-induced nephrotic syndrome in a patient with multiple sclerosis. *Clin Nephrol.* 2000; 54(5):425-6.
40. Goldschmidt N, Azaz-Livshits T, **Gotsman I**, Nir-Paz R, Ben-Yehuda A, Muszkat M. Compound cardiac toxicity of oral erythromycin and verapamil. *Ann Pharmacother* 2001; 35(11):1396-9.
41. Shapira MY, Braunstein I, Mushkat M, **Gotsman I**. Co-occurrence of Hepatocellular Carcinoma and Lymphoma in a patient with hepatitis c virus cirrhosis. *J Clin Gastroenterol.* 2001; 32(4):368-9.
42. **Gotsman I**, Verstandig A. Intravascular stent implantation of the celiac artery in the treatment of chronic mesenteric ischemia. *J Clin Gastroenterol.* 2001; 32(2):164-6.
43. **Gotsman I**, Goral A, Nasair S. Secondary spontaneous pneumothorax in a patient with pulmonary rheumatoid nodules during treatment with Methotrexate. *Rheumatology* 2001; 40(3):350-1.
44. **Gotsman I**, Gilon D, Elami A. Transesophageal echocardiography of a large tricuspid valve vegetation: a perfect image of reality. *Heart.* 2003 Jun;89(6):696..
45. Meirovitz A, **Gotsman I**, Lilling M, Bogot NR, Fridlender Z, Wolf DG. Osteomyelitis of the pubis after strenuous exercise. A case report and review of the literature. *J Bone Joint Surg Am.* 2004 May;86-A(5):1057-60.
46. **Gotsman I**, Mosseri M. Acute myocardial infarction in a young woman with normal coronary arteries and a combined thrombophilia. *International Journal of Cardiology* 2005 Mar 30;99(3):483-4.
47. **Gotsman I**, Keren A, Admon D. Cardiogenic shock in an elderly woman: a diagnostic and therapeutic challenge. *Isr Med Assoc J* 2011;13:773-5. (Impact Factor: 0.9)
48. **Gotsman I**, Helman Y, Planer D. Acute stent thrombosis after a "stroll for fresh air" : A case of the smoking gun. *Herz* 2012.

Letters & other:

49. **Gotsman I**, Ilan Y. Downregulation of a tumor promotion immune response via induction of oral tolerance towards tumor-associated-antigens: can we “eat the tumor”. *Medical Hypothesis* 2001; 56(4):487-92.
50. Fridlender ZG, **Gotsman I**. Pleural Effusion. *N Engl J Med*. 2002; 347(16):1286-1287.
51. **Gotsman I**. Cytokines and coronary artery disease. *Isr Med Assoc J*. 2009;11:65-65

Non peer-reviewed papers:

52. **Gotsman I**, Haviv Y, Nir-Paz R. Low-dose Bezafibrate-associated myositis in a patient with chronic renal failure. *Clin Drug Invest*. 1999; 18:481-483.
53. **Gotsman I**, Jurim O, Trop S, Pappo O, Ilan Y. The effect of peripheral immune tolerance induction on liver-associated-lymphocytes expressing NK1.1. *Transplant Proc*. 2000; 32(4): 749-750.
54. **Gotsman I**, Gotsman MS. Myocardial salvage is incomplete after reperfusion in acute myocardial infarction. *Coronary artery Proc*. 2000; 45-52.
55. **Gotsman I**, Muszkat M, Fridlender Z, Meirovitz A, Gotsman M. The diagnosis of an exudative pleural effusion in congestive heart failure. *Coronary artery Proc*. 2000; 611-618.
56. **Gotsman I**, Gotsman MS. Ebb-and-flow in the circulation: the Galen hypothesis. *J Isr Heart Soc* 2002; 11(3): 18-20
57. **Gotsman I**, Lotan C. Stem cells regenerate viable tissue after myocardial infarction. *J Isr Heart Soc* 2002; 11(3): 21-22.
58. **Gotsman I**, Gotsman MS. Atherosclerosis - An Immune-mediated Inflammatory Disease? *J Isr Heart Soc* 2002; 12(1): 21-25.
59. **Gotsman I**, Keren A. Fulminant lymphocytic myocarditis versus giant cell myocarditis. European Society of Cardiology, Myocardial and Pericardial Diseases Working Group Clinical case of the month – (ePub) 2008.
60. **Gotsman I**, Alcalai A. Acute heart failure – an update (Hebrew).
עדכונים בטיפול באיטסיפקת לב חריפה - *Harefua update – Cardiology* 2011; 4: 27-30.

Abstracts - International

1. **Gotsman I**, Trop S, Samsonov D, Alper R, Diment J, Ilan Y. Liver associated lymphocytes expressing NK1 .1 are essential for oral immune tolerance induction in a murine model. Presented at The European Association for the Study of The Liver, Naples, 1999. Abstract in *Journal of Hepatology*, 30:63, 1999. (Oral presentation).
2. **Gotsman I**, Beinart R, Safadi R, Engelhardt D, Rabani E, Shouval D, Gorecki M, Roy Chowdhury N, Roy Chowdhury J, Ilan Y. Oral tolerance towards Hepatitis B antigens in a murine model. Presented at the American Gastroenterology Association Meeting, Digestive-Disease- Week, Orlando 1999. *Gastroenterology*, 116:A1216, 1999. (Poster)
3. Jurim O, **Gotsman I**, Trop S, Pappo O, Ilan Y. Peripheral immune tolerance induces liver associated-lymphocytes expressing NK1 .1. Presented at the **American Society of Transplantation**, Chicago, 1999.
4. **Gotsman I**, Samsonov D, Trop S, Yurin O, Alper R, Diment J, Engelhardt D, Rabani E, Ilan Y. Liver mediated immunomodulation in a murine model: The role of NK1.1+ Liver associated lymphocytes in peripheral tolerance induction. Presented at the American Association for the Study of Liver Diseases, Dallas 1999. *Hepatology* 30:495A, 1999. (Poster)
5. Nagler A, **Gotsman I**, Pines M, Beinart R, Alper R, Zeira M, Rabani E, Engelhardt D, Roy Chowdhury N, Roy Chowdhury J, Ilan Y. Induction of oral tolerance in splenocyte recipients towards pre-transplant splenocyte antigens ameliorates chronic graft versus host disease in a murine model. Presented at the American Association for the Study of Liver Diseases, Dallas 1999. *Hepatology* 30:426A, 1999. (Oral presentation).
6. **Gotsman I**, Alper R, Rabani E, Engelhardt D, Ilan Y. Induction of oral tolerance enables growth of the hepatoma cell line in mice. Presented at the plenary session at the European Association for the Study of The Liver meeting, Rotterdam, 2000. Abstract in *Journal of Hepatology*, 32 (supp. 2): 34, 2000. (Oral presentation).
7. **Gotsman I**, Nagler A, Beinart R, Pines M, Abadi U, Pappo O, Zeira M, Rabani E, Engelhardt D, Roy Chowdhury N, Roy Chowdhury J, Ilan Y. Induction of oral tolerance prior or following bone marrow transplantation ameliorates chronic graft

- versus host disease in a murine model. Presented at The American Gastroenterology Association Meeting, Digestive-Disease- Week, San Diego 2000. Abstract in *Gastroenterology*, 2000. (Oral presentation).
8. **Gotsman I**, Gotsman M. Myocardial salvage is incomplete after reperfusion in acute myocardial infarction. Presented at the 3rd international congress on coronary artery disease. Lyon 2000. (Poster)
 9. **Gotsman I**, Muszkat M, Fridlender Z, Meirovitz A, Gotsman M. The diagnosis of an exudative pleural effusion in congestive heart failure. Presented at the 3rd international congress on coronary artery disease. Lyon 2000. (Poster)
 10. **Gotsman I**, Nagler A, Beinart R, Pines M, Abadi U, Rabbani E, Engelhardt D, Ilan Y. Induction of oral tolerance prior to or following bone marrow transplantation ameliorates chronic graft versus host disease in a murine model. *Gastroenterology*. 2000; 118:A357-A357. (Poster)
 11. **Gotsman I**, Alper R, Klein A, Engelhardt D, Rabbani E, Ilan Y. Induction of oral immune-regulation towards hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice. Presented at The American Association for the Study of The Liver annual meeting, Dallas, USA 2000. *Hepatology*. 2000; 32:206A-206A. (Oral presentation).
 12. **Gotsman I**, Ilan Y, Muszkat M. Glucose-6-dehydrogenase deficiency increases the severity of viral hepatitis A. Presented at The American Association for the Study of The Liver annual meeting, Dallas, USA 2000. *Hepatology* 32: 383A, 2000. (Poster)
 13. **Gotsman I**, Meirovitz A, Meizilsh N, Gotsman M, Lotan C, Gilon D. Current predictors of morbidity and mortality in infective endocarditis. Presented at The American Heart Association annual meeting, Chicago, USA 2002. *Circulation*. 2002; 106:547-547. (Poster)
 14. **Gotsman I**, Stabholz A, Soskolne WA, Rassovsky S, Pugatsch T, Lapidus L, Novikov Y, Masrawa S, Lotan C. Coronary artery disease is associated with periodontal destruction and acute coronary syndromes are associated with the periodontal pathogen porphyromonas gingivalis. *Circulation*. 2005; 112:U689-U690. (Poster)
 15. **Gotsman I**, Grabie N, DaCosta R, Lichtman A. The role of the T-cell inducible co-stimulatory molecule ICOS in the development of atherosclerosis. Oral presentation in San-francisco 2006. *Faseb Journal*. 2006; 20:A199-A199. (Oral presentation).

16. **Gotsman I**, Grabie N, DaCosta R, Sharpe A, Lichtman AH. Deficiency of the regulatory molecules PD-L1 and PD-L2 results in increased atherosclerosis in LDLR-null mice. Presented at The American Heart Association annual meeting, Chicago, USA 2006. *Circulation*. 2006; 114:286-286. (Oral presentation).
17. Rocha VZ, Folco EJ, Sukhova G, Shimizu K, **Gotsman I**, Vernon AH, Libby P. Interferon-gamma, a th1 cytokine, regulates fat inflammation: A role for adaptive immunity in obesity. *Circulation*. 2008;118:S467-S467
18. Zwas D, **Gotsman I**, Alcalai A, Keren A, Benderly M. Predictive value of pulse pressure in patients with acute coronary syndrome. Presented at the **European Society of Cardiology** annual meeting, Barcelona 2009. (Poster)
19. **Gotsman I**, Zwas D, Admon D, Lotan C, Keren A. Seasonal Variations in Hospital Admission in Patients with Heart Failure and its Effect on Prognosis. Presented at the **European Society of Cardiology** annual meeting, Barcelona 2009. (Poster)
20. **Gotsman I**, Zwas D, Admon D, Lotan C, Keren A. The predictive value of serum urea and renal function in patients with heart failure. Presented at the **European Society of Cardiology** annual meeting, Barcelona 2009. (Poster)
21. **Gotsman I**, Zwas D, Zemora Z, Admon D, Jabara R, Lotan C, Keren A. Clinical outcome of patients with chronic heart failure followed in a specialized heart failure center. Presented at the **European Heart Failure Congress** annual meeting, Gotenburg 2011. (Poster)
22. **Gotsman I**, Zwas D, Admon D, Lotan C, Keren A. Hyperuricemia in heart failure: Associated with increased E/A ratio and predictor of increased risk for adverse outcome. Presented at the **European Heart Failure Congress** annual meeting, Gotenburg 2011. (Poster)
23. **Gotsman I**, Zwas D, Admon D, Lotan C, Keren A. Impaired fasting glucose: a predictor of increased morbidity and mortality in patients with heart failure. Presented at the **European Society of Cardiology** annual meeting, Paris 2011. (Oral presentation).
24. **Gotsman I**, Ezra O, Zwas D, Helman Y, Lotan C, Keren A. Improved clinical outcome in patients followed in a hospital-based heart failure center. Presented at the **European Heart Failure Congress** annual meeting, Belgrade 2012. (Poster)

25. Shauer A, Zwas DR, Hellman Y, Keren A, Lotan C, Admon D, **Gotsman I**. Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. Presented at the **European Heart Failure Congress** annual meeting, Belgrade 2012. (Poster)
26. **Gotsman I**, Zwas D, Helman Y, Banker J, Admon D, Lotan C, Keren A. Electrocardiographic frontal QRS/T angle is a highly significant predictor of increased morbidity and mortality in patients with chronic heart failure. To be presented at the **European Society of Cardiology** annual meeting, Munich 2012. (Poster)

Abstracts - Local

27. **Gotsman I**, Jurim O, Trop S, Pappo O, Ilan Y. Peripheral immune tolerance induces liver associated-lymphocytes expressing NK1 .1. Presented at the **Israel Society of Transplantation**, 1999.
28. Trop S, Samsonov D, **Gotsman I**, Alper R, Diment J, Ilan Y. Liver associated lymphocytes expressing NK1 .1 are essential for oral immune tolerance induction. Presented at the **Israel Association for the Study of the Liver**, 1999.
29. **Gotsman I**, Nagler A, Pines M, Abadi U, Pappo O, Zeira M, Engelhardt D, Rabani E, Roy Chowdhury N, Roy Chowdhury J, Ilan Y. Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease. Presented at the Israeli Gastroenterology Association Meeting, Eilat, 1998. Abstract in *European Journal of Gastroenterology and Hepatology* 11:A6, 1999. (Oral presentation).
30. **Gotsman I**, Jurim O, Trop S, Pappo O, Ilan Y. The effect of peripheral immune tolerance induction on liver-associated-lymphocytes expressing NK1 .1. Presented at The Israel Transplantation Association Meeting. Abstract in *Transp Proceedings* 1999.
31. **Gotsman I**, Beinart R, Alper R, Engelhardt D, Rabani E, Ilan Y. Induction of Oral tolerance towards Hepatitis B envelope antigens in the presence of pre-existing immunity. Presented at the Israel Gastroenterology Association Meeting, Eilat, 1999. Abstract in *European Journal of Gastroenterology and Hepatology* 2000. (Oral presentation).

32. **Gotsman I**, Samsonov D, Trop S, Yurin O, Alper R, Diment J, Engelhardt D, Rabani E, Ilan Y. Liver mediated immunomodulation in a murine model: The role of NK1.1+ Liver associated lymphocytes in peripheral tolerance induction. Presented at the **Israeli Association for the Study of the Liver**, 2000. (Oral presentation).
33. **Gotsman I**, Menachem Y, Shlomai A, Alper R, Rabbani E, Engelhardt D, Ilan Y. Amelioration of immune-mediated experimental colitis: Tolerance induction in the presence of pre-existing immunity and surrogate antigen bystander effect. Presented at the **Israeli Gastroenterology Association Meeting**, Israel, 2000. (Oral presentation).
34. **Gotsman I**, Admon D, Pollak A, Varshitsky B, Gilon D, Elami A, Milgalter E, Lotan C. Ventricular septal defect complicating acute myocardial infarction: clinical presentation, electrocardiographic features and outcome. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2001.
35. **Gotsman I**, Fridlender Z, Muszkat M, Meirovitz A, Gotsman M. The evaluation of pleural effusion in congestive heart failure and the relation to diuretics. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2001.
36. **Gotsman I**, Lotan C, Meirovitz A, Meizlish N, Gilon D. Clinical manifestation of Infective Endocarditis in a Tertiary University Hospital in the Last Decade. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2002. (Oral presentation).
37. **Gotsman I**, Pugatsch T, Barak V, Lapidus L, Novikov Y, Masrawa S, Lotan C. The Cytokine Profile of Patients with Stable versus Unstable Coronary Syndromes. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2002.
38. **Gotsman I**, Lotan C, Gotsman MS, Mosseri M. Clinical Manifestations and Outcome of Acute Myocardial Infarction in Very Young Patients. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2002.
39. **Gotsman I**, Lotan C, Meirovitz A, Meizlish N, Gilon D. Improved Survival rate in Patients with Infective Endocarditis in the Last Decade. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2002. (Oral presentation).
40. **Gotsman I**, Pugatsch T, Barak V, Lapidus L, Novikov Y, Masrawa S, Lotan C. Cytokines, CRP and Inflammatory Markers are Significantly Elevated in Acute

Coronary Syndromes and Acute Myocardial Infarction. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2003.

41. **Gotsman I**, Rassevsky S, Lapidus L, Novikov Y, Masrawa S, Pugatsch T, Soskolne AW, Stabholz A, Lotan C. Chronic Periodontal Disease Predicts the Presence and Severity of Coronary Artery Disease and Both are Directly Related to Tumor Necrosis Factor Alpha. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2003.
42. **Gotsman I**, Dror N, Meir K, Alper R, Lotan C, Ilan Y, Leitersdorf E. Induction of Oral Tolerance towards Atherosclerotic Plaque Antigens (Oxidized-LDL) Attenuates Atherosclerosis in Apo-E-Deficient Mice. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2003. (Oral presentation).
43. **Gotsman I**, Stabholz A, Pugatsch T, Soskolne WA, Rassevsky S, Lapidus L, Novikov Y, Masrawa S, Lotan C. Serum Cytokines Tumor Necrosis Factor Alpha and Interleukin-6 are Associated with Coronary Artery Disease: Indicators of a Chronic Active Inflammatory Burden? Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2004. (Oral presentation).
44. **Gotsman I**, Grabie N, Gupta R, Dacosta R, Sukhov G, Witztum JL, Sharpe AH, Lichtman AH. T-Cell Response and Enhanced Atherosclerosis in the Absence of Inducible Costimulatory Molecule. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2007.
45. **Gotsman I**, Grabie N, DaCosta R, Sharpe A, Lichtman AH. Deficiency of the regulatory molecules PD-L1 and PD-L2 results in increased atherosclerosis in LDLR-null mice. Oral Presentation, the **Israel Heart Society** annual meeting, Jerusalem, Israel 2007. (Oral presentation).
46. Potekhin M, **Gotsman I**, Ofman P, Rogin N, Dan Admon MD, Rosenheck S, Beeri R, Gilon D, Pollak A, Lotan C, Alcalai R, Keren A. Hypertrophic Cardiomyopathy with Extreme Left Ventricular Hypertrophy: Risk Profile and Outcome With and Without ICD Implant. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2008. (Oral presentation).
47. **Gotsman I**, Azaz-Livshits T, Shani R, Keren A. The Clinical Outcome of Patients with Congestive Heart Failure: A Poor Prognosis Despite Preserved Left Ventricular

- Function. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2008. (Oral presentation).
48. **Gotsman I**, Shani R, Azaz-Livshits T. The Utilization of ACE Inhibitors and ARB in Patients with Congestive Heart Failure: An Observational Study of Treatment Rates and Clinical Outcome. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2008. (Oral presentation).
 49. **Gotsman I**, Zwas D, Admon D, Lotan C, Keren A. Seasonal Variations in Hospital Admission in Patients with Heart Failure and its Effect on Prognosis. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2009. (Oral presentation).
 50. Admon D, **Gotsman I**, Varshitsky B, Zwas D, Potekhin M, Gilon D, Pollak A, Lotan C, Keren A. The Clinical Presentation and Outcome of Acute Myocarditis: Are Women With Myocarditis Sicker? Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2009. (Oral presentation).
 51. Admon D, **Gotsman I**, Varshitsky B, Zwas D, Potekhin M, Gilon D, Pollak A, Lotan C, Keren A. Long Term Follow up of Percutaneous Coronary Interventions in Heart Transplant Recipients. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2009. (Oral presentation).
 52. Keren A, Potekhin M, **Gotsman I**, Zwas D, Mosseri M, Beeri R, Leibowitz D, Levin G, Danenberg H, Pollak A, Admon D, Lotan C. Clinical and Hemodynamic Outcome of Inferobasal Wall Injury Complicating Alcohol Septal Ablation in Hypertrophic Cardiomyopathy. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2009. (Oral presentation).
 53. **Gotsman I**, Zwas D, Admon D, Lotan C, Keren A. The Significance of Serum Urea and Renal Function in Patients with Heart Failure. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2009. (Oral presentation).
 54. Zwas D, Benderly M, Elizur Y, Ilieva R, **Gotsman I**, Alcalai A, Keren A, Lotan C. Predictive Value of Pulse Pressure in Patients with Acute Coronary Syndrome. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2009.
 55. Zwas D, Geldman Y, **Gotsman I**, Potekhin, M; Ezra O, Admon D, Levy S, Lotan C, Keren A. Impact of Sleep Disturbances on Quality of Life in Heart Failure Patients. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2010.

56. Zemora Z, **Gotsman I**, Zwas D, Jabara R, Gwertzman H, Admon D, Lotan C, Keren A. The Impact of a Nurse-supervised Heart Failure Clinic Program on Compliance and Functional Capacity of Patients with Chronic Heart Failure. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2010. (Oral presentation).
57. **Gotsman I**, Zwas D, Admon D, Lotan C, Keren A.. Long Term Clinical Outcome of Heart Failure and Preserved Left Ventricular Function. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2010.
58. **Gotsman I**, Zwas D, Admon D, Lotan C, Keren A. The Prognostic Significance of Right Ventricular Function in Chronic Heart Failure. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2010. (Oral presentation).
59. **Gotsman I**, Zwas D, Zemora Z, Jabara R, Admon D, Lotan C, Keren A. The Clinical Outcome of Patients with Chronic Heart Failure Followed in a Specialized Heart Failure Center. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2010. (Oral presentation).
60. **Gotsman I**, Zwas D, Admon D, Lotan C, Keren A. Impaired fasting glucose: a predictor of increased morbidity and mortality in patients with heart failure. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2011. (Oral presentation).
61. **Gotsman I**, Zwas D, Admon D, Lotan C, Keren A. Hyperuricemia in Heart failure: Associated with Increased E/A ratio and Predictor of Increased Risk for Adverse Outcome. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2011.
62. Shauer A, Zwas DR, Helman Y, Keren A, Lotan C, Admon D, **Gotsman I**. Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2012.
63. **Gotsman I**, Ezra O, Zwas D, Helman Y, Lotan C, Keren A. Improved Clinical Outcome in Patients Followed in a Hospital-Based Heart Failure Center. Presented at the **Israel Heart Society** annual meeting, Jerusalem, Israel 2012. (Oral presentation).